{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Complete response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"26"}]}],"title":"Progressive disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}],"title":"Stable disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"}],"units":"Participants"}],"description":"Response is assessed by the RECIST (response criteria in solid tumors)criteria. A complete response (CR) is disappearance of all target lesions , partial response (PR) is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, progressive disease (PD) is at least a 20% increase in the sum of the LD of target lesions, and stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.","groups":[{"description":"200 mg BID was the administered dose for the initial part of the study and then a phase I dose escalation was added with 100 mg as the starting dose.","id":"OG000","title":"Multi-kinase Inhibitor Fosamatinib Disodium"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"24 months","title":"Response Rate","type":"PRIMARY","unitOfMeasure":"Participants"}